PR NEWSWIRE

Previous Stories

BLUETTI FridgePower Is Now Available on Its Official Australian Website

Sep 02 2026 - PR NewsWire

A 75mm ultra-slim UPS backup battery that raised US$2.2 million from 1,800 Kickstarter backers SYDNEY, Sept. 2, 2026 /PRNewswire/ – BLUETTI,…


Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway

Sep 02 2026 - PR NewsWire

The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment…


Chemonics Australia Expands Public Sector Advisory, Infrastructure, and Development Delivery Capabilities with Acquisitions of 35 South and JID

Sep 02 2026 - PR NewsWire

The acquisitions strengthen Chemonics Australia’s ability to support governments, development partners, and institutions across Australia and the Indo-Pacific with practical…


97% METHANE GAS STRENGTHENS CASE FOR MAJOR NEW WA ONSHORE GAS SYSTEM

Sep 02 2026 - PR NewsWire

PERTH, Australia, Sept. 2, 2026 /PRNewswire/ — A 12-year-old exploration drill hole in Western Australia’s Gascoyne is still venting gas containing…


JAMS Software Launches JAMS Incident Management for On-Call Alerting and Escalation

Sep 02 2026 - PR NewsWire

Alerts escalate through the on-call rotation until someone answers. Free for up to five users, with paid plans starting at…


XO Sports Xplodes into the USA

Sep 01 2026 - PR NewsWire

The Australian AI predictions platform that called four out of five underdogs in the NBA Finals has landed on American…


Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunothera

Sep 01 2026 - PR NewsWire

Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a…


Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in H

Sep 01 2026 - PR NewsWire

Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of…


TWOTEN BALLARAT PTY LTD ANNOUNCES OFFERING OF AUD 5,159,576 JUNIOR SECURED LOAN NOTE OFFER

Sep 01 2026 - PR NewsWire

MELBOURNE, Australia, Sept. 1, 2026 /PRNewswire/ — TwoTen Ballarat Pty Ltd ACN 653 946 760 (the Issuer) is seeking to…


TWOTEN BALLARAT PTY LTD ANNOUNCES OFFERING OF AUD 48,055,484 SENIOR SECURED LOAN NOTE OFFER

Sep 01 2026 - PR NewsWire

MELBOURNE, Australia, Sept. 1, 2026 /PRNewswire/ — TwoTen Ballarat Pty Ltd ACN 653 946 760 (the Issuer) is seeking to…


Analyse The Market From A Different Angle